天津医药 ›› 2017, Vol. 45 ›› Issue (7): 709-714.doi: 10.11958/20170451

• 临床研究 • 上一篇    下一篇

蒲参胶囊对缺血性脑卒中患者血脂及动脉粥样硬化的影响

刘晶,崔建华,刘首峰   

  1. 1 天津市南开区中医医院 (邮编 300102); 2 天津市环湖医院
  • 收稿日期:2017-04-11 修回日期:2017-05-19 出版日期:2017-07-15 发布日期:2017-08-08
  • 基金资助:
    国家体育总局科研课题 (2015B098)

Efficacy of pushen capsule on blood lipid and atherosclerosis in patients with ischemic stroke

LIU Jing,CUI Jian-hua,LIU Shou-feng   

  1. 1 Nankai Hospital of Traditional Chinese Medicine, Tianjin 300102, China; 2 Tianjin Huanhu Hospital
  • Received:2017-04-11 Revised:2017-05-19 Published:2017-07-15 Online:2017-08-08

摘要: 目的 探讨蒲参胶囊对缺血性脑卒中患者血脂及动脉粥样硬化的影响。方法 将 120 例缺血性脑卒中 患者随机分为治疗组 (蒲参胶囊+瑞舒伐他汀钙)、 对照 1 组 (蒲参胶囊)、 对照 2 组 (瑞舒伐他汀钙), 各 40 例, 疗程为6 个月。检测 3 组治疗前后血清总胆固醇(TC)、 三酰甘油(TG)、 高密度脂蛋白胆固醇 (HDL-C)、 低密度脂蛋白胆固醇(LDL-C)、 同型半胱氨酸(Hcy), 超敏 C 反应蛋白(hs-CRP)、 一氧化氮(NO)、 内皮素-1(ET-1)、 颈动脉斑块数量、大小、 厚度和内膜中层厚度(IMT)的变化, 观察不良脑血管事件和不良反应的发生情况, 并进行血脂异常疗效评价。结果 与治疗前比较, 3 组治疗后各指标均有明显改善(均 P<0.05)。组间比较, 治疗前各指标差异均无统计学意义; 治疗后, 与对照 1 组比较, 对照 2 组 TG、 NO 升高、 LDL-C、 斑块大小、 厚度降低, 治疗组 TC、 LDL-C、 Hcy、 hs-CRP、ET-1、 斑块数量、 大小、 厚度、 IMT 均降低, NO 升高(P<0.05); 与对照 2 组比较, 治疗组 TG、 LDL-C、 hs-CRP、 斑块数量、 大小、 厚度降低, HDL-C、 NO 升高(P<0.05)。3 组药物不良反应和不良脑血管事件发生率差异无统计学意义。治疗组总有效率高于对照 1 组 (P<0.05), 治疗组与对照 2 组、 对照 2 组与对照 1 组间差异无统计学意义。结论 蒲参胶囊联合瑞舒伐他汀钙可有效降低缺血性脑卒中患者的血脂, 抗动脉粥样硬化作用明显, 效果确切, 且安全性良好。

关键词: 卒中, 动脉粥样硬化, 高脂血症, 药物疗法, 缺血性脑卒中, 蒲参胶囊, 瑞舒伐他汀钙

Abstract: Objective To explore the efficacy of pushen capsule on blood lipid and atherosclerosis in patients with ischemic stroke. Methods One hundred and twenty patients with ischemic stroke were randomly divided into three groups,treatment group (pushen capsule and rosuvastatin calcium), control group- 1 (pushen capsule) and control group- 2 (rosuvastatin calcium). There were 40 patients for each group. The course of treatment was 6 months. Data of serum total cholesterol (TC), triacylglycerol (TG), high density lipoprotein cholesterol (HDL- C), low density lipoprotein cholesterol (LDL- C), homocysteine (Hcy), high sensitive C reactive protein (hs- CRP), nitric oxide (NO), endothelin - 1 (ET- 1), the number and size of carotid plaques, and changes of intima-media thickness (IMT) were detected before and after treatment in three groups. The incidences of adverse cerebrovascular events and adverse events were observed in the three groups. And the therapeutic effects for dyslipidemia were evaluated in three groups. Results The treatment indicators were obviously improved after treatment in three groups (P<0.05). There were no significant differences in treatment indicators before treatment between three groups. The levels of TG and NO increased, the level of LDL-C, the size and thickness of carotid plaques decreased after treatment in control group-2 than those of control group-1. Levels of TC, LDL-C, Hcy, hs-CRP,ET-1, IMT, and the number, size and thickness of carotid plaques were significantly lower in treatment group than those of control group- 1 (P<0.05), and the level of NO was higher in treatment group than that of control group- 1 (P<0.05).Compared with control group-2, levels of TG, LDL-C, hs-CRP and the number, size and thickness of carotid plaques were significantly lower, and levels of HDL-C and NO were significantly increased in treatment group (P<0.05). There were no significant differences in the incidences of adverse drug reactions and adverse cerebrovascular events between the three groups (P>0.05). The total effective rate was higher in treatment group than that of control group-1 (P<0.05). There wereno significant differences in total effective rates between treatment group and control group-2, and between control group-2and control group-1 (P>0.05). Conclusion Pushen capsule combined with rosuvastatin calcium can obviously improve blood lipid metabolism in patients with ischemic stroke, which shows obvious antiatherosclerosis effect and good safety.

Key words: stroke, atherosclerosis, hyperlipidemias, drug therapy, ischemic stroke, Pushen capsule, rosuvastatin calcium

中图分类号: